Details of Disease

General Information of Disease (ID: DISBICMY)

• Disease Name: Advanced solid tumour
• Disease Class: 2A00-2F9Z: Solid tumour/cancer
• Disease Hierarchy:
  DIS01GPL: Grass pollen hypersensitivity
  DISBICMY: Advanced solid tumour
• ICD Code:
  ICD-11: ICD-11: 2A00-2F9Z
  ICD-9: ICD-9: 140-199
  Expand ICD-9: 1.40E+179

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 11 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
ABC294640	DMCKPG4	Phase 3	Small molecular drug	[1]
TVB-2640	DM19GUH	Phase 2	NA	[2]
CLR457	DM64FY7	Phase 1/2	NA	[3]
NM21-1480	DMDNJP5	Phase 1/2	Antibody	[4]
X-396	DMZ9VCF	Phase 1/2	Small molecular drug	[5]
ABT-700	DMVLPRT	Phase 1	NA	[6]
BTX-A51	DMC8XHQ	Phase 1	Small molecular drug	[7]
CBL0137	DMORN60	Phase 1	NA	[8]
CEP-37250	DM72N3N	Phase 1	NA	[9]
GSK1070916	DMXRPT6	Phase 1	Small molecular drug	[10]
TEN010	DM4UOY5	Phase 1	NA	[11]

This Disease is Treated as An Indication in 5 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
AZD6918	DM2QHVW	Discontinued in Phase 1	NA	[12]
PF-03814735	DMO4S6T	Discontinued in Phase 1	Small molecular drug	[13]
PF-477736	DMDOTW0	Discontinued in Phase 1	Small molecular drug	[14]
R547	DMK25FU	Discontinued in Phase 1	Small molecular drug	[15]
ZK 304709	DMJ9R4A	Discontinued in Phase 1	Small molecular drug	[16]

Molecular Interaction Atlas (MIA) of This Disease

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6624).
• [2] ClinicalTrials.gov (NCT02223247) A Phase 1, First-In-Human Study of Escalating Doses of Oral TVB-2640 in Patients With Solid Tumors. U.S. National Institutes of Health.
• [3] ClinicalTrials.gov (NCT02189174) Study of CLR457 Administered Orally in Adult Patients With Advanced Solid Malignancies. U.S. National Institutes of Health.
• [4] ClinicalTrials.gov (NCT04442126) A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
• [5] ClinicalTrials.gov (NCT01625234) Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer. U.S. National Institutes of Health.
• [6] ClinicalTrials.gov (NCT01472016) Study of ABT-700 in Subjects With Advanced Solid Tumors. U.S. National Institutes of Health.
• [7] ClinicalTrials.gov (NCT04872166) A Study of BTX-A51 in People With Advanced Solid Tumor or Non-Hodgkin Lymphoma. U.S. National Institutes of Health.
• [8] ClinicalTrials.gov (NCT01905228) A Phase 1 Trial of CBL0137 in Patients With Metastatic or Unresectable Advanced Solid Neoplasm or Refractory Lymphomas. U.S. National Institutes of Health.
• [9] ClinicalTrials.gov (NCT01447732) Phase 1 Study of CEP-37250/KHK2804 in Subjects With Advanced Solid Tumors. U.S. National Institutes of Health.
• [10] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8358).
• [11] ClinicalTrials.gov (NCT02308761) A Dose Escalation and Cohort Expansion Study of TEN-010 in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome. U.S. National Institutes of Health.
• [12] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028850)
• [13] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025628)
• [14] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8043).
• [15] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5707).
• [16] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022386)
• [17] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7816).